ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.95096
0.04%
Brent Oil
84.085
0.65%
Bitcoin
57,788.02
-0.77%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. NovoCure Ltd (NVCR)

  7. NovoCure Ltd (NVCR) Noticias

NVCR NovoCure Ltd

12.74
0.00 (0.00%)
Pre Mercado
Última actualización: 03:10:56
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
NovoCure Ltd NVCR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 12.74 03:10:56
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
12.74
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202409:45BWResults of Novocure’s METIS Phase 3 Clinical Trial for..
05/4/202406:00BWNovocure Announces 20 Presentations On Tumor Treating..
01/4/202406:00BWNovocure to Report First Quarter 2024 Financial Results
28/3/202419:07BWMETIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
28/3/202412:51BWKlinische Phase-3-Studie METIS erreicht primären Endpunkt..
28/3/202412:50BWL’essai clinique de phase 3 METIS a atteint son critère..
27/3/202406:00BWMETIS Phase 3 Clinical Trial Met Primary Endpoint,..
11/3/202406:00BWINNOVATE-3 Late Breaking Abstract Selected as a Best Oral..
05/3/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202417:39EDGAR2Form 144 - Report of proposed sale of securities
04/3/202416:56EDGAR2Form 144 - Report of proposed sale of securities
01/3/202416:06EDGAR2Form 144 - Report of proposed sale of securities
01/3/202416:01EDGAR2Form 144 - Report of proposed sale of securities
29/2/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202406:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202406:06EDGAR2Form 8-K - Current report
22/2/202406:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202406:00BWNovocure Reports Fourth Quarter and Full Year 2023 Financial..
18/1/202410:10DJNNovocure Shares Rise 17% After FDA Accepts Pre-Market..
18/1/202406:01EDGAR2Form 8-K - Current report
18/1/202406:00BWNovocure Announces FDA Acceptance of the PMA Application for..
12/1/202415:57EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/1/202406:00EDGAR2Form 8-K - Current report
09/1/202406:00BWNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT..
08/1/202406:10EDGAR2Form 8-K - Current report
08/1/202406:00BWNovocure Announces Preliminary Full Year and Fourth Quarter..
04/1/202415:10EDGAR2Form 8-K - Current report
04/1/202415:05BWNovocure Appoints Dr. Nicolas Leupin as Chief Medical..
27/12/202306:00BWNovocure to Participate in 42nd Annual J.P. Morgan..
28/11/202306:30EDGAR2Form 8-K - Current report
28/11/202306:30BWNovocure Announces Portfolio Prioritization and Strategic..
21/11/202306:00BWNovocure to Participate in 35th Annual Piper Sandler..
10/11/202307:00BWNovocure Announces Presentations on Tumor Treating Fields..
08/11/202315:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202315:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202306:03EDGAR2Form 8-K - Current report
26/10/202306:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26/10/202306:00BWNovocure Reports Third Quarter 2023 Financial Results
15/10/202317:05BWNovocure Announces Presence at European Society for Medical..
12/10/202307:00BWNovocure and Stanford School of Medicine to Establish Tumor..
02/10/202306:00BWNovocure to Report Third Quarter 2023 Financial Results
29/9/202316:00BWNovocure Announces Presence at American Society for..
08/9/202315:01BWNovocure Highlights Use of Tumor Treating Fields Therapy in..
05/9/202315:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202315:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
NVCR
NovoCure
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados